Mosquitoes, especially Aedes aegypti, are a health problem because they transmit diseases such as dengue, chikungunya and zika. The control of the pest has been performed through physical and chemical methods, but the excessive use of chemicals has generated resistance in the mosquito. An alternative to control with synthetic insecticides is the use of phytoextracts. In this patent, the extract of quinolizidine alkaloids of Lupinus campestris on larvae L1 and L3 of Aedes aegypti was evaluated. The results showed that the quinolizidine alkaloid extract has larvicidal activity, has a teratogenic effect, increases the duration of larval instars and determines the sex ratio, causing the null emergence of female adults, unlike Temefos (r) that has a female-male ratio at 2:1. This result is important, since females are vectors-transmitters of the viruses that cause the aforementioned diseases, with which the quinolizidine alkaloid extract would be helping to reduce by 50% the number of vector-transmitting individuals in a population. In addition, the females are the ovipositors, so it would reduce the density of the populations of this vector in a proportion that no other product invented to date achieves. The results demonstrate that quinolizidine alkaloid extract is an alternative for controlling Aedes aegypti.
展开▼
